Invivyd is a biotech developing antibody treatments for infectious diseases, with its lead candidate, adintrevimab, in Phase 3 trials for COVID-19 prevention and treatment. It's a clinical-stage company, meaning its products aren't on the market yet.
The company generates minimal revenue—just USD 0.05B in 2025—but spends heavily on R&D, posting a net loss of USD 0.05B that year. With negative margins (net margin around -98%), it's burning cash and not yet profitable.
Invivyd's potential edge lies in its proprietary antibody platform and partnerships with Adimab and Scripps, but this is unproven. Competitors like Regeneron and AstraZeneca already sell COVID antibodies, making Invivyd's position weak until clinical success.
Key events, in time order
Cantor's Schimmer issues new note with $10 PT, highlighting COVID transmission trends' impact on trial
None yet
None yet
Invivyd is holding a speculative position ahead of Phase 3 data, anticipating positive results driven by current vaccine hype and a potential COVID-19 spike.
Main discussion
Different voices
$IVVD planning to hold all of my lotto position through PH3 data due next month. My downside risk is around $0.5 if data disappoints. Positive news will send shares a lot higher keeping in mind current hype in vaccines followed by $MRNA news and stock reaction. Please do your own
RT @semodough: $IVVD on Biobeats today Schimmer saying “spike in Covid tracker likely pretends positive data by end of quarter 🤷♂️
$IVVD on Biobeats today Schimmer saying “spike in Covid tracker likely portends positive data by end of quarter 🤷♂️
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
